The study of therapeutic drug development with neurodegenerative diseases by using iPS cells derived from patients' samples.
Not Applicable
Recruiting
- Conditions
- eurodegenerative diseases
- Registration Number
- JPRN-UMIN000038561
- Lead Sponsor
- Gifu Pharmaceutical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
<Amyotrophic lateral sclerosis (ALS)> Exclude the following diseases. Other motor neuron disorders, motor neurophathy, cervical spondylosis, and inflammatory myopathy such as inclusion body myositis. <Idiopathic basal ganglia calcification (IBGC)> To exclude diseases which show calcification, because of some causes such as hypoparathyroism, pseudo hypoparathyroism, pseudopseudo hypoparathyroism (Albright's osteodystrophy), Down syndrome, collagen diseases, angiitis, infections, intoxication, trauma, radiation therapy and so on.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To lay the foundation for future researches of drug development for neurodegenerative diseases.
- Secondary Outcome Measures
Name Time Method